Emergent BioSolutions Secures Long-Term Strategic Manufacturing Contract with SAB Biotherapeutics to Advance Type 1 Diabetes Candidate, SAB-142
Go back to Emergent BioSolutions Secures Long-Term Strategic Manufacturing Contract with SAB Biotherapeutics to Advance Type 1 Diabetes Candidate, SAB-142| EMERGENT BIOSOLUTIONS, Inc. (NYSE: EBS) | Delayed: 8.32 -0.07 (0.83%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $8.39 | 52 Week High | $44.38 | |||
| Open | $8.33 | 52 Week Low | $24.47 | |||
| Day High | $8.47 | P/E | 416.00 | |||
| Day Low | $8.27 | EPS | $0.02 | |||
| Volume | 476,663 | |||||
| (NASDAQ: SABS) | Delayed: 3.33 -0.05 (1.48%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $3.38 | 52 Week High | $ | |||
| Open | $3.40 | 52 Week Low | $ | |||
| Day High | $3.55 | P/E | N/A | |||
| Day Low | $3.33 | EPS | $ | |||
| Volume | 356,433 | |||||
